Get the Stockscreener App
16.68
1.58%
0.26
Urogen Pharma Ltd stock is traded at $16.68, with a volume of 1.41M.
It is up +1.58% in the last 24 hours and down -12.72% over the past month.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
See More
Previous Close:
$16.42
Open:
$16.5
24h Volume:
1.41M
Relative Volume:
1.20
Market Cap:
$771.69M
Revenue:
$82.71M
Net Income/Loss:
$-102.24M
P/E Ratio:
-4.545
EPS:
-3.67
Net Cash Flow:
$-76.57M
1W Performance:
-4.14%
1M Performance:
-12.72%
6M Performance:
+77.64%
1Y Performance:
+40.05%
1-Day Range:
$15.86
$16.89
1-Week Range:
$15.86
$17.61
52-Week Range:
$3.42
$21.71
Urogen Pharma Ltd Stock (URGN) Company Profile
Name
Urogen Pharma Ltd
Sector
Industry
Phone
972 9 770 7601
Address
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
16.68 | 759.66M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Jun-16-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-22-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-19-25 | Resumed | Ladenburg Thalmann | Buy |
| Aug-22-24 | Initiated | Guggenheim | Buy |
| Feb-08-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-27-22 | Initiated | Berenberg | Buy |
| Apr-16-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-09-20 | Initiated | National Securities | Neutral |
| May-30-19 | Initiated | JP Morgan | Neutral |
| May-29-19 | Initiated | Goldman | Neutral |
| Jan-29-19 | Initiated | H.C. Wainwright | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Apr-04-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jan-02-18 | Initiated | Ladenburg Thalmann | Buy |
| Nov-15-17 | Reiterated | Oppenheimer | Outperform |
| Nov-15-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
View All
Urogen Pharma Ltd Stock (URGN) Latest News
Using AI based signals to follow UroGen Pharma Ltd.Long Setup & Fast Exit/Entry Strategy Plans - newser.com
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Cuts Target Price to $36 - 富途牛牛
Bender Robert & Associates Invests $475,000 in Urogen Pharma $URGN - MarketBeat
What technical models suggest about UroGen Pharma Ltd.’s comebackJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Chris Degnan Sells 2,203 Shares of Urogen Pharma (NASDAQ:URGN) Stock - MarketBeat
Understanding UroGen Pharma Ltd.’s price movementEarnings Beat & Safe Swing Trade Setups - newser.com
Is UroGen Pharma Ltd. reversing from oversold territoryJuly 2025 Breakouts & Weekly High Return Opportunities - newser.com
Is UroGen Pharma Ltd. (UR8) stock a momentum leaderJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for Urogen Pharma (NASDAQ:URGN) - MarketBeat
UroGen Pharma CFO Degnan sells $37k in shares By Investing.com - Investing.com UK
UroGen Pharma CFO Degnan sells $37k in shares - Investing.com
Is UroGen Pharma Ltd. (UR8) stock worth holding before Fed meeting2025 Geopolitical Influence & Weekly Breakout Watchlists - newser.com
UroGen continues to climb after bladder cancer drug approval - MSN
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues - Sahm
Why UroGen Pharma Ltd. (UR8) stock trades below fair value2025 Analyst Calls & Consistent Profit Trade Alerts - newser.com
Is UroGen Pharma Ltd a good long term investmentVolatility Index Analysis & Consistent Triple Returns - earlytimes.in
UroGen Pharma Ltd. stock outlook for YEARPortfolio Value Report & Intraday High Probability Setup Alerts - newser.com
How to recover losses in UroGen Pharma Ltd. stock2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Can swing trading help recover from UroGen Pharma Ltd. lossesJobs Report & High Accuracy Swing Entry Alerts - newser.com
NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com
UroGen Pharma (URGN): Maintained Buy Rating by D. Boral Capital | URGN Stock News - GuruFocus
Urogen Pharma (NASDAQ:URGN) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Why UroGen Pharma Ltd. (UR8) stock stays on buy listsMarket Risk Analysis & Scalable Portfolio Growth Methods - newser.com
UroGen’s bladder cancer treatment shows durable response in clinical trials By Investing.com - Investing.com Nigeria
Can machine learning forecast UroGen Pharma Ltd. recoveryAnalyst Downgrade & Weekly Setup with ROI Potential - newser.com
ZUSDURI™ Clinical Review Published in Reviews in Urology™ - GlobeNewswire
Can IL FS Transportation Networks Limited Deliver Margin Expansion Amid InflationEquity Performance Review & Small Investment Portfolio Tips - earlytimes.in
What drives UroGen Pharma Ltd stock priceStock Market Trends & Smart Beta Strategies That Actually Work - earlytimes.in
URGN: UroGen Pharma's ZUSDURI Shows Promising Results for Bladder Cancer - GuruFocus
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer - GlobeNewswire
Urogen Pharma (NASDAQ:URGN) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Urogen Pharma (NASDAQ:URGN) Trading Down 5.9%Here's Why - MarketBeat
UroGen Pharma Hits Day High with 15.59% Surge, Outperforming S&P 500 - Markets Mojo
Urogen Pharma Ltd Stock (URGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Urogen Pharma Ltd Stock (URGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schoenberg Mark | Chief Medical Officer |
Sep 08 '25 |
Sale |
19.11 |
871 |
16,645 |
149,025 |
| Smith Jason Drew | General Counsel |
Sep 08 '25 |
Sale |
19.11 |
1,520 |
29,047 |
43,305 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):